Partners News Strategic partnership Enzyre BV and Takeda for better diagnostics for bleeding disorders

16 April 2021

Strategic partnership Enzyre BV and Takeda for better diagnostics for bleeding disorders

Takeda announced to have entered into a strategic partnership with Enzyre BV, a Radboudumc spin-off company. The partnership aims to accelerate the development of a diagnostic technology platform that improves the standard of care for patients with bleeding disorders.

Enzyre was founded in 2016 with the mission to save patients from bleeding to death with their Enzypad technology. Their vision is to create a point of care diagnostic platform that will measure a multitude of enzymatic reactions based on chemiluminescence.

Read the Takeda announcement here: https://lnkd.in/dJSqpRk

Related news items


Job opportunity: Program Manager Health Incubator at SMB

17 January 2023

Science Meets Business (SMB) is looking for a community builder to manage and expand the incubator and maintain relationships with the stakeholders.

read more

Aftermovie Investment Day 2022 and a new date for 2023!

13 December 2022

Over 100 scientists, investors, and entrepreneurs came together to accelerate innovation in healthcare by creating new business opportunities and forging strong public-private partnerships.

read more

Enzyre closes Series A financing round of €12M to advance pioneering diagnostic technology platform for hemophilia patients

2 November 2022

Enzyre has announced that it has successfully raised €12 million in a Series A financing led by new investor, Oost NL, with participation from i&i Biotech Fund, Demcon Investment, Takeda Ventures, and Novalis Biotech. Part of the funding is an Innovation Credit from the Dutch Government.

read more

Successful matchmaking at Radboudumc Investment Day  

7 October 2022

On the 5th of October, over 100 scientists, investors and entrepreneurs came together at the second Radboudumc Investment Day, jointly hosted by Radboudumc, Oost NL and Briskr.

read more

SPL Medical announces collaboration with NanoEcho for application of Ferrotran® (Ferumoxtran) for Ultrasound detection of Lymph node metastases

30 September 2022

SPL medical and NanoEcho have signed a Letter of Intent and initiated a cooperation on regulatory partnership and supply for SPL medical proprietary iron-based nanoparticle Ferrotran® (Ferumoxtran) product and platform.

read more

Radboudumc Investment Day 2022

26 September 2022

Get ready for Radboudumc Investment Day 2022: October 5 in Nijmegen!

read more